GlassScriptPhysician profile
Ashley Mills
NPI 1780839548
$1,626.82
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $704 · 2022: $574 · 2023: $162 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.98 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $341.51 | 2021-2022 | |
| Boston Scientific Corporation | $179.64 | 2021-2023 | |
| Corium, LLC | $161.01 | 2022-2023 | Azstarys |
| Alkermes, INC. | $109.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $79.66 | 2021-2022 | |
| Lundbeck LLC | $59.06 | 2021-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $46.87 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.21 | 2024 | Caplyta |
| Gilead Sciences, INC. | $34.14 | 2024 | Epclusa |
| Emd Serono, INC. | $30.56 | 2021 | |
| Tris Pharma INC | $24.04 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $20.74 | 2021 | |
| Almatica Pharma LLC | $18.34 | 2021 | |
| Neos Therapeutics, LP | $18.15 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.07 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.06 | 2024 | Fanapt |
| Tolmar, INC. | $13.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.